My Application Form StatusCheck the status of your application form with Angel Broking.
Procter & Gamble Hygiene and Health Care (P&G)’s 3QFY2016 results are broadly in-line with our estimates. For the quarter, the company’s top-line grew by ~11% yoy to Rs614cr while the reported PAT grew ~12% yoy to Rs97cr. Key highlights: For 3QFY2016, the company’s top-line grew by ~11% yoy to ~Rs614cr (against our estimate of ~Rs624cr), mainly due to growth in both female hygiene and health care segment. On the operating front, the company reported margin contraction by 41bp yoy to 21.7%, primarily on account of higher other expenses. The reported net profit grew by ~12% yoy to ~Rs97cr (our estimate was of ~Rs98cr) on account of healthy sales growth. Outlook and valuation: On the top-line front, we expect the company to report ~13% CAGR and on the bottom-line front, we expect ~15% CAGR over FY2015- 18E on the back of strong brands and distribution network. Further, P&G is a market leader in both of its product, ie Whisper (female hygiene segment) and Vicks (healthcare segment- ointment, creams, cough drops etc). We are positive on the stock and recommend a Buy rating with a target price of Rs7,369.Download Full Report
|Investment Period||12 Months|
|MCAP BSE (Rs in Cr)||22,719.59|
|MCAP NSE (Rs in Cr)||22,822.49|
|Div Yield (%)||0.51|
Shareholding Pattern (%)
|Public & Others||11.0|